| Literature DB >> 17673814 |
Fukuto Maruta1, Satoshi Ishizone, Manabu Hiraguri, Yoshiro Fujimori, Fumiaki Shimizu, Shigeyoshi Kumeda, Shinichi Miyagawa.
Abstract
We conducted a clinical pilot study to evaluate the efficacy and safety of the combination of docetaxel and 5'DFUR as a second-line chemotherapy for gastric cancer. Twenty-four patients were divided into two groups by simple randomization: group A (60 mg/m2 of docetaxel, every 3 wk) and group B (regimen A + 600 mg/body of 5'DFUR). The response rate was 17% and 42% in group A and B, respectively (p < 0.05). The MST from the start of the first-line was 17 mo in group B. The major adverse event was leukopenia in both groups.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17673814 DOI： 10.1007/BF02685905
Source DB: PubMed Journal: Med Oncol ISSN： 1357-0560 Impact factor: 3.064